Profil
Marina Udier currently works at Nouscom AG, as Chief Executive Officer & Director from 2020, Nouscom Srl, as Chief Executive Officer & Director, and Celyad Oncology SA, as Independent Director from 2011.
Dr. Udier also formerly worked at Novartis AG, as Head-Global Commercial and Versant Venture Management LLC, as Chief Operating Officer.
Dr. Udier received her doctorate degree from Yale University.
Aktiva positioner av Marina Udier
| Företag | Position | Start |
|---|---|---|
| CELYAD ONCOLOGY SA | Direktör/Styrelseledamot | 2011-01-11 |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Verkställande Direktör | 2019-05-01 |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Verkställande Direktör | - |
Tidigare kända positioner av Marina Udier
| Företag | Position | Slut |
|---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Verksamhetschef | - |
| NOVARTIS AG | Företagsledare/Principal | - |
Marina Udiers utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 6 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Celyad Oncology SA
Celyad Oncology SA BiotechnologyHealth Technology Develops immuno-oncology and cardiology products | Health Technology |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Health Technology |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Commercial Services |
















